Cellenkos, Inc. Initiates Phase 1 Clinical Trial of CK0801 for...
HOUSTON, June 4, 2019 /PRNewswire-AsiaNet/ -- Cellenkos, Inc.(http://www.cellenkosinc.com/), announced today the initiation of a Phase 1 Clinical Trial of CK0801, a first-in-class, allogeneic cord blood-derived T-regulatory cell product, for treatment of patients with bone marrow failure synd...
Authors: LATEST ASIANET NEWS RELEASES